StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Beam Therapeutics's price to book ratio was 2.5× on Nov 11, 2026, against 2.7× a year earlier. Over the last 5 years it ranged from 1.4× to 6.5×, with a median of 2.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.5×−0.4
2025Dec 31, 20252.9×+0.3
2024Dec 31, 20242.6×−0.2
2023Dec 29, 20232.8×−1.1
2022Dec 30, 20223.9×−2.5
2021Dec 31, 20216.3×−14.3
2020Dec 31, 202020.6×–

More Beam Therapeutics figures

See a number that looks wrong?